# An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol

> **NCT02564952** · PHASE2 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** GWP42003-P
- **DRUG:** Clobazam

## Key facts

- **NCT ID:** NCT02564952
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-11
- **Primary completion:** 2017-06-07
- **Final completion:** 2017-06-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02564952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02564952, "An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02564952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*